Catalyst Wire Dossier Catalyst Wire Dossier

LYBALVI

olanzapine and samidorphan L-malate · Alkermes, Inc.
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for LYBALVI, covering 2021-05-28 to 2026-01-30. Get the full timeline:

Most recent: FDA Approved: LYBALVI — Supplemental Application (Alkermes, Inc.)

See pricing